Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Nicholas J. Viney(Ionis Pharmaceuticals (United States)), Julian C. van Capelleveen(Academic Medical Center), Richard S. Geary(Ionis Pharmaceuticals (United States)), Shuting Xia(Ionis Pharmaceuticals (United States)), Joseph A. Tami(Ionis Pharmaceuticals (United States)), Rosie Z. Yu(Ionis Pharmaceuticals (United States)), Santica M. Marcovina(University of Washington), Steven G. Hughes(Ionis Pharmaceuticals (United States)), Mark J. Graham(Ionis Pharmaceuticals (United States)), Rosanne M. Crooke(Ionis Pharmaceuticals (United States)), Stanley T. Crooke(Ionis Pharmaceuticals (United States)), Joseph L. Witztum(University of California, San Diego), Erik S.G. Stroes(Academic Medical Center), Sotirios Tsimikas(Ionis Pharmaceuticals (United States))
The Lancet
September 22, 2016
Cited by 743

Abstract


Related Papers

No related papers found

Powered by citation graph analysis